Literature DB >> 6269824

Potential value of cefoperazone in bacterial meningitis: experimental studies.

D T Durack, J R Perfect.   

Abstract

To assess the potential value of cefoperazone in treating bacterial meningitis, its pharmacokinetics in the cerebrospinal fluid of rabbits were studied. Cefoperazone penetrated poorly into the cerebrospinal fluid of rabbits with uninflamed meninges, but in the presence of meningitis concentrations increased 2- to 3-fold. These concentrations were above the minimum inhibitory concentrations for the majority of Enterobacteriaceae, indicating the potential value of cefoperazone in treating bacterial meningitis. The half-lives of cefoperazone and moxalactam in cerebrospinal fluid, measured by a bioassay, were marked prolonged by meningeal inflammation. In contrast, the half-life of cefotaxime in cerebrospinal fluid was short. Consequently both cefoperazone and moxalactam provided significantly better antibacterial effect in cerebrospinal fluid than did cefotaxime.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6269824     DOI: 10.2165/00003495-198100221-00013

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  10 in total

1.  Assessment of antibiotic efficacy in acute bacterial meningitis.

Authors:  T R Beam; J C Allen
Journal:  Clin Pharmacol Ther       Date:  1979-02       Impact factor: 6.875

2.  Inhibition of penicillin transport from the cerebrospinal fluid after intracisternal inoculation of bacteria.

Authors:  R Spector; A V Lorenzo
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

3.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

4.  Diffusion of a new beta-lactam (LY 127935) into cerebrospinal fluid. Implications for therapy of gram-negative bacillary meningitis.

Authors:  S H Landesman; M L Corrado; C C Cherubin; M Gombert; D Cleri
Journal:  Am J Med       Date:  1980-07       Impact factor: 4.965

5.  A study of cephalothin and desacetylcephalothin in cerebrospinal fluid in therapy for experimental pneumococcal meningitis.

Authors:  C M Nolan; W C Ulmer
Journal:  J Infect Dis       Date:  1980-03       Impact factor: 5.226

6.  Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli.

Authors:  S D Lang; D J Edwards; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

7.  Comparison of cefamandole, cephalothin, ampicillin, and chloramphenicol in experimental Escherichia coli meningitis.

Authors:  T R Beam; J C Allen
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

8.  Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis.

Authors:  U B Schaad; G H McCracken; C A Loock; M L Thomas
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

9.  Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins.

Authors:  R Wise; P J Wills; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

10.  Intravenous cefotaxime in children with bacterial meningitis.

Authors:  B H Belohradsky; K Bruch; D Geiss; D Kafetzis; W Marget; G Peters
Journal:  Lancet       Date:  1980-01-12       Impact factor: 79.321

  10 in total
  4 in total

1.  Role of serum protein binding and multiple antibiotic doses in the extravascular distribution of ceftizoxime and cefotaxime.

Authors:  D N Gerding; L L Van Etta; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

3.  Pharmacokinetic evaluation of cefoperazone in infants.

Authors:  M Varghese; A J Khan; K Kumar; W Rosenfeld; H A Schaeffer; H E Evans
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

Review 4.  Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; A Carmine; R C Heel; P A Morley; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-12       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.